ProCE Banner Series

Addressing Challenges With Adherence and Persistence to Oral Anticancer Therapies in Patients With Breast Cancer

Register now and gain insights into the factors influencing adherence and persistence to oral anticancer therapies in patients with breast cancer. Discover strategies to evaluate and overcome adherence challenges and access recommendations for effectively managing adverse events through certified Medical Minute video modules, expert-written ClinicalThought commentaries, and downloadable slides.

  AAPA
  | ACPE
  | ANCC
Who Should Attend

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, advanced degree nurses who manage patients, and pharmacists who are part of the care team for patients with breast cancer.

All Events

Addressing Challenges With Adherence and Persistence to Oral Anticancer Therapies in Patients With Breast Cancer

Upcoming Events

May

19

2025

6:00 PM - 7:30 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in identifying and addressing factors that affect adherence and persistence to oral therapies for breast cancer.

Target Audience
This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, advanced degree nurses who manage patients, and pharmacists who are part of the care team for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess fundamental issues that affect adherence and persistence to oral anticancer therapy for patients with breast cancer, including patient-, provider- and treatment-related factors and socioeconomic considerations and healthcare disparities

  • Use communication strategies, tools, and resources to assess and address adherence challenges in patients on oral anticancer therapies for breast cancer

  • Apply evidence-based recommendations to effectively mitigate and manage AEs associated with oral anticancer therapies in breast cancer

  • Initiate discussions with patients with breast cancer and their caregivers to assess for and reinforce education on treatment-related AEs and maintain adherence and persistence to prescribed oral anticancer therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours, including 1.5 hours of pharmacotherapy credit.

Continuing Pharmacy Education

Partners designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008073-0000-25-129-L01-P

Type of Activity: Application

Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.  

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest 
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies. 

Acknowledgement

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC. 

Provided by

Provided by PACE in partnership with Practicing Clinicians Exchange, LLC. and Clinical Care Options, LLC 

Clinical Care Options, LLC
Partners for Advancing Clinical Education (PACE) 2025

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC. 

AstraZeneca

Merck Sharp & Dohme, LLC

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191